Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on transforming the treatment of rare neuroendocrine diseases. Its lead product, IMCIVREE (setmelanotide), is an MC4R agonist approved by the FDA to reduce excess body weight and maintain weight reduction in adult and pediatric patients with acquired hypothalamic obesity (ages 4+), as well as patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed POMC, PCSK1, or LEPR deficiency (ages 2+). IMCIVREE is also authorized in the EU and UK for BBS and genetic obesity indications, and in the EU for acquired hypothalamic obesity. The company is advancing a pipeline of MC4R agonists including bivamelagon (a daily oral candidate) and RM-718 (a weekly injectable candidate), as well as a preclinical suite of small molecules for congenital hyperinsulinism. Rhythm commercializes IMCIVREE globally, with primary revenue from the United States and growing international sales across Europe and other markets, with a Japan launch anticipated by year-end 2026. Updated Aug 4, 2026